Archer-1: 100% ORR ( 3/3 complete response CR). Vanvittig!!


Nordic Nanovector R&D Day unveils updates on several programs

2019-09-17 07:00 GMT+02

Clinical

LYMRIT 37-01 (relapsed iNHL) - median duration of response of 13.6 months for all responders and 32.0 months for complete responders versus 9.0 months and 20.7 months respectively reported last December at ASH

Archer-1 - 100% ORR (3/3 complete response (CR)) in the first cohort of patients in a phase 1b study of Betalutin® + rituximab in relapsed/refractory follicular lymphoma
Preclinical

NOK 6 million in Eurostars funding granted for taking the chimeric alpha-particle emitting anti-CD37 radioimmunoconjugate Alpha37 through the last step towards clinical testing

Superior efficacy of Alpha37 with respect to market leading ibrutinib has been shown in an ibrutinib-resistant mouse model of chronic lymphocytic leukemia (CLL)
Redigert 17.09.2019 kl 07:09 Du må logge inn for å svare

3 pasienter er for tynt grunnlag. Det blir sammenliknet med Xofigo og det var denne artikkelen i NEJM som var toppen på kransekaka som markerte gjennombruddet dog med over 900 pasienter. https://www.nejm.org/doi/full/10.1056/NEJMoa1213755
Det er verdt å merke seg at radium-223 var en alfa-emitter i likhet med NNV003 hvor museforsøkene er spektakulære.
Redigert 20.09.2019 kl 20:12 Du må logge inn for å svare